

## AMENDMENT

### In the Specification:

✓ At page 4, line 16, delete "ATTC No. \_\_\_\_" and insert therefor -- ATCC No. HB 10519 --.

✓ At page 21, line 11, delete "No. \_\_\_\_" and insert therefor -- No. HB 10519 --.

### In the Abstract:

✓ At page 29, line 18, delete "ATTC No. \_\_\_\_" and insert therefor -- ATCC No. HB 10519 --.

### In the Title:

Please delete "IL-4 ACTS SYNERGISTICALLY WITH IL-1 $\beta$  TO PROMOTE LYMPHOCYTE ADHESION TO MICROVASCULAR ENDOTHELIUM BY INDUCTION OF" and insert therefor --METHODS FOR USING AGENTS THAT BIND TO--.

### In the Claims:

✓ Please cancel claims 1-4 without prejudice to applicants' right to pursue a claim of the same or similar scope in a duly filed continuing application.

Please amend claims 17-18 as follows:

B1  
17. (Amended) A therapeutic method of modulating the immune response in a patient, which comprises administering to the patient an agent that specifically binds to IL4-activated microvascular endothelial cells, in an amount effective to impede transmigration of cells that [specifically] bind to VCAM-1 from blood across postcapillary venules into extracellular fluid in the patient.

2/1  
cont.

18. (Amended) The method of Claim 17, wherein the cells that bind to VCAM-1 are lymphocytes [agent is administered in an amount effective to impede transmigration of lymphocytes across postcapillary venules in the patient].

Please add the following claims 19-30:

--19. The method of claim 17, wherein the cells that bind to VCAM-1 are bone marrow cells.

22

--20. The method of claim 17, wherein the agent is selected from the group consisting of monoclonal antibodies and antigen-binding fragments of said monoclonal antibodies that specifically bind to a mAb-6G10-recognized epitope of a cell surface molecule, and wherein mAb-6G10 is the monoclonal antibody produced by hybridoma ATCC No. HB 10519.

--21. The method of claim 20, wherein the agent is the monoclonal antibody 6G10 produced by hybridoma ATCC No. HB 10519.

--22. A method of modulating interaction between a VCAM-1-expressing cell and a cell that binds to VCAM-1 which comprises administering an agent selected from the group consisting of monoclonal antibodies and antigen-binding fragments of said monoclonal antibodies that specifically bind to a mAb-6G10-recognized epitope of a cell surface molecule, wherein mAb-6G10 is the monoclonal antibody produced by hybridoma ATCC No. HB 10519, in an amount effective to decrease adhesion between the cell that binds to VCAM-1 and the VCAM-1-expressing cell.

--23. The method of claim 22, wherein the agent is the monoclonal antibody 6G10 produced by hybridoma ATCC No. HB 10519.

--24. The method of claim 22, wherein the VCAM-1-expressing cell is a microvascular endothelial cell and the cell that binds to VCAM-1 is a peripheral blood lymphocyte.

--25. The method of claim 22, wherein the VCAM-1-expressing cell is a human umbilical vein endothelial cell and the cell that binds to VCAM-1 is a lymphocyte.

--26. The method of claim 22, wherein the VCAM-1-expressing cell is a microvascular endothelial cell in a lymphoid organ and the cell that binds to VCAM-1 is a lymphocyte or bone marrow cell.

--27. The method of claim 22, wherein the VCAM-1-expressing cell is a bone marrow stromal cell and the cell that binds to VCAM-1 is a bone marrow cell.

--28. The method of claim 27, wherein the bone marrow cell expresses the CD34 antigen.

--29. The method of claim 27, wherein the bone marrow cell is a stem cell or progenitor cell.

--30. A method of modulating interaction between a bone marrow stromal cell and a bone marrow cell which comprises administering an agent that specifically binds to VCAM-1, in an amount effective to decrease adhesion between the bone marrow stromal cell and the bone marrow cell.